European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

Summary by AI BETAClose X

The European Commission has authorized Pfizer and BioNTech's 2026-2027 COVID-19 vaccine formula targeting the XFG variant for individuals six months and older, following a recommendation from the European Medicines Agency's Emergency Task Force. This authorization, valid across all 27 EU Member States plus Iceland, Liechtenstein, and Norway, is based on data demonstrating a strong immune response against contemporary circulating and emerging lineages, alongside a favorable safety and efficacy profile. Manufacturing has commenced to ensure timely access for the upcoming respiratory disease season, with over five billion doses of Pfizer-BioNTech COVID-19 vaccines already distributed globally.

Disclaimer*

UK 100

Latest directors dealings